Optovue, a Fremont, Ca. maker of devices that improve diagnosis and treatment of ocular disease, has received $10.5 million in second round of funding, the company announced said.
Based on high speed and high resolution Fourier-Domain OCT technology, the products help with retina conditions such as macular degeneration, diabetic retinopathy, glaucoma, and other macular diseases.
Trevi Health Ventures led the round, which also included Acorn Campus Ventures, HNQ Asia Pacific, Harbinger Venture Management, iD SoftCapital and other individual investors. Optovue raised about $4.5 million in a first round.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more